Keryx Announces Results of Data Safety Monitoring Committee and Collaborative Study Group (CSG) Review of First Interim Analysis From Phase II/III Clinical Program for KRX-101 (Oral Sulodexide) for the Treatment of Diabetic Nephropathy (PR Newswire, 2005)
Keywords: Anticoagulants; Biological products; Clinical trials; Collaboration; Diabetes; Diabetic nephropathy; Drug dosages; FDA approval; Kidney diseases; Patients; New York